Portal Access, a startup on oncology-oriented medical devices, concluded a financing round of $ 7 million Series A.
The company said that more than 80% of the round was led by American doctors’ investors, including oncologists, interventional radiologists, cardiologists and vascular surgeons.
Extra investors are, among other things, a partnership of a non -mentioned American risk capital fund.
What it does
The company produces Flexi Port SLF-Tanl, a subcutaneous port that has been developed to streamline vascular access for patients with oncology.
The company will use the funds to support a 510 (K) entry at the FDA for Flexi Port SLF-Tanl, the company that says it is expected in July 2025, planned for 2026 with an American market launch.
In a statement, Portal said the Flexi Port SLF-TANL device can help minimize delays, procedural risks and total healthcare costs.
“Closing this financing round is an important milestone if we work on the approval of the regulations,” Michael Tal, founder and CEO of Portal Access, said in a statement.
“Flexi-Poort SLF-Tanl is designed with a focus on simplicity, stability and scalability, which probably support more efficient workflows in the access settings of oncology. It is a solution for both clinics and patients and created with the most optimal patient outcome and experience in mind. “
Market Snapshot
Other companies in the oncology space include Atropos Health, who announced a strategic partnership in April with OntaDa, a McKesson company involved in community discology. Oncology Network is connected to the US Oncology Network, which provides data, insights and research into how cancer is treated in a community.
Also in April, Concertai announced a multi -year agreement with pharmaceutical and biotechnology -giant Bayer to use Concertai’s Translational360 and AI Saas offers.
The offer uses AI and Machine Learning insights to accelerate clinical development in precision oncology.
The Agreement is intended to use Concertai’s Translational360 offer, an integrated, research level, longitudinal clinical molecular database that use the Cancancerlinq network of anonymized data of anonymous cancer patients from more than 9 million records in all 50 states.
In March, Flatiron Health collaborated with NRG Oncology, a clinical research consortium within the National Clinical Trials Network of the National Cancer Institute, which has more than 1,300 research sites worldwide to use a Flatiron clinical pipe in a multi -center NRG clinical study.
Flatiron Clinical Pipe is an electronic health file (EPD) for electronic data replacement (EDC) connector aimed at improving efficiency and reducing the time and efforts required for entering clinical study data.
The collaboration was aimed at broadening the use cases of Flatiron Clinical Pipe with NCTN sponsored studies by applying Flatiron’s EHR-to-EDC technology to reduce the burden on NRG teams for clinical test locations, to facilitate data management and speed up research.
#Portal #Access #protects #million #Chemotherapiepoort